Wang Z, Farooq A, Chen Y, Bhargava A, Xu A, Thomson M
Nat Biomed Eng. 2025; .
PMID: 40044819
DOI: 10.1038/s41551-025-01357-0.
Kuo C, Giannikou K, Wang N, Warren M, Goodspeed A, Shillingford N
bioRxiv. 2025; .
PMID: 39975230
PMC: 11838416.
DOI: 10.1101/2025.01.31.635996.
Sun Y, Yee E, Fujiwara Y, Dickinson K, Guo Y, Sun Z
J Immunother Cancer. 2025; 13(1.
PMID: 39805660
PMC: 11749055.
DOI: 10.1136/jitc-2024-010554.
Semilietof A, Stefanidis E, Gray-Gaillard E, Pujol J, DEsposito A, Reichenbach P
J Immunother Cancer. 2025; 12(12.
PMID: 39794936
PMC: 11667476.
DOI: 10.1136/jitc-2024-009504.
Goncalves M, Warwas K, Meyer M, Schwartz-Albiez R, Bulbuc N, Zornig I
Cancers (Basel). 2025; 16(24.
PMID: 39766150
PMC: 11674949.
DOI: 10.3390/cancers16244251.
Dual ON/OFF-switch chimeric antigen receptor controlled by two clinically approved drugs.
Giordano Attianese G, Shui S, Cribioli E, Triboulet M, Scheller L, Hafezi M
Proc Natl Acad Sci U S A. 2024; 121(44):e2405085121.
PMID: 39453747
PMC: 11536088.
DOI: 10.1073/pnas.2405085121.
Optogenetically engineered Septin-7 enhances immune cell infiltration of tumor spheroids.
Chen J, Hnath B, Sha C, Beidler L, Schell T, Dokholyan N
Proc Natl Acad Sci U S A. 2024; 121(44):e2405717121.
PMID: 39441641
PMC: 11536090.
DOI: 10.1073/pnas.2405717121.
Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment.
Baharom F, Hermans D, Delamarre L, Seder R
Nat Rev Immunol. 2024; 25(3):195-211.
PMID: 39433884
DOI: 10.1038/s41577-024-01091-9.
Using Spectral Flow Cytometry for CAR T-Cell Clinical Trials: Game Changing Technologies Enabling Novel Therapies.
Beadnell T, Jasti S, Wang R, Davis B, Litwin V
Int J Mol Sci. 2024; 25(19).
PMID: 39408593
PMC: 11476793.
DOI: 10.3390/ijms251910263.
Bioprinting of Cells, Organoids and Organs-on-a-Chip Together with Hydrogels Improves Structural and Mechanical Cues.
Mierke C
Cells. 2024; 13(19.
PMID: 39404401
PMC: 11476109.
DOI: 10.3390/cells13191638.
Targeting CD276 for T cell-based immunotherapy of breast cancer.
Hagelstein I, Wessling L, Rochwarger A, Zekri L, Klimovich B, Tegeler C
J Transl Med. 2024; 22(1):902.
PMID: 39367484
PMC: 11452943.
DOI: 10.1186/s12967-024-05689-4.
A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies.
Wu J, Bloch N, Chang A, Bhavsar R, Wang Q, Crawford A
Cell Rep Med. 2024; 5(10):101747.
PMID: 39326410
PMC: 11513833.
DOI: 10.1016/j.xcrm.2024.101747.
Acidity suppresses CD8 + T-cell function by perturbing IL-2, mTORC1, and c-Myc signaling.
Vuillefroy de Silly R, Pericou L, Seijo B, Crespo I, Irving M
EMBO J. 2024; 43(21):4922-4953.
PMID: 39284912
PMC: 11535206.
DOI: 10.1038/s44318-024-00235-w.
Carbohydrate-Lectin Interactions Reprogram Dendritic Cells to Promote Type 1 Anti-Tumor Immunity.
Lensch V, Gabba A, Hincapie R, Bhagchandani S, Basak A, Alam M
ACS Nano. 2024; 18(39):26770-26783.
PMID: 39283240
PMC: 11646345.
DOI: 10.1021/acsnano.4c07360.
Cancer-Associated-Fibroblast-Mediated Paracrine and Autocrine SDF-1/CXCR4 Signaling Promotes Stemness and Aggressiveness of Colorectal Cancers.
Chen C, Yang S, Chang P, Chen S, Nieh S, Huang W
Cells. 2024; 13(16.
PMID: 39195225
PMC: 11352219.
DOI: 10.3390/cells13161334.
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors.
Holtermann A, Gislon M, Angele M, Subklewe M, von Bergwelt-Baildon M, Lauber K
BioDrugs. 2024; 38(5):611-637.
PMID: 39080180
PMC: 11358237.
DOI: 10.1007/s40259-024-00669-y.
Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers.
Gu X, Zhang Y, Zhou W, Wang F, Yan F, Gao H
Exp Hematol Oncol. 2024; 13(1):70.
PMID: 39061100
PMC: 11282638.
DOI: 10.1186/s40164-024-00542-2.
Biophysical modeling identifies an optimal hybrid amoeboid-mesenchymal phenotype for maximal T cell migration speeds.
Alonso-Matilla R, Provenzano P, Odde D
bioRxiv. 2024; .
PMID: 39026744
PMC: 11257493.
DOI: 10.1101/2023.10.29.564655.
The identification of effective tumor-suppressing neoantigens using a tumor-reactive TIL TCR-pMHC ternary complex.
Kim S, Lee B, Kim S, Kim S, Kim M, Kim J
Exp Mol Med. 2024; 56(6):1461-1471.
PMID: 38866910
PMC: 11263684.
DOI: 10.1038/s12276-024-01259-2.
Combining SiRPα decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells.
Stefanidis E, Semilietof A, Pujol J, Seijo B, Scholten K, Zoete V
J Clin Invest. 2024; 134(11).
PMID: 38828721
PMC: 11142748.
DOI: 10.1172/JCI161660.